De­nali touts more bio­mark­er da­ta with ac­cel­er­at­ed ap­proval in mind

He­paran sul­fate, a po­ten­tial new sur­ro­gate bio­mark­er for neu­rode­gen­er­a­tive dis­eases, is get­ting a lot of love from biotechs this week.

De­nali Ther­a­peu­tics on Wednes­day pre­sent­ed new da­ta for its lead pro­gram, aim­ing to prove how re­duc­tions in he­paran sul­fate, a car­bo­hy­drate whose ex­cess and tox­ic buildup is caused by ge­net­ic mu­ta­tions, can re­li­ably pre­dict a clin­i­cal ben­e­fit for pa­tients. The com­pa­ny’s up­date came one day af­ter Ul­tragenyx re­vealed da­ta for an ex­per­i­men­tal drug in a dif­fer­ent dis­ease for which he­paran sul­fate may al­so be a po­ten­tial sur­ro­gate bio­mark­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER